Company: BIVIW
Filing Date: 2025-05-15
Form Type: DRS
Source: 0001520138-25-000149
Chunk: 59

Company: BIOVIE INC.
Filing Date: 2025-05-15
Form: DRS
Chunk 59
---
 upon for us by Fennemore Craig, P.C.
Certain legal matters related to this offering will be passed upon for the underwriters by Sheppard, Mullin, Richter & Hampton LLP.

<div align='center'>Experts</div>

The balance sheets of BioVie Inc. as of June 30,
2024 and 2023, and the related statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows
for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their
report which is incorporated by reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning
the Company’s ability to continue as a going concern. Such financial statements have been incorporated by reference in reliance
on the report of such firm given upon their authority as experts in accounting and auditing.

<div align='center'>Where You Can Find
More Information</div>

We have filed with the SEC a registration statement
on Form S-1 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which constitutes a part
of the registration statement, does not contain all of the information set forth in the registration statement, some of which is contained
in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to
us and our securities, we refer you to the registration statement, including the exhibits filed as a part of the registration statement.
Statements contained in this prospectus concerning the contents of any contract or any other document is not necessarily complete. If
a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that
has been filed. Each statement is this prospectus relating to a contract or document filed as an exhibit is qualified in all respects
by the filed exhibit. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers,
like us, that file electronically with the SEC. The address of that website is www.sec.gov.

We are subject to the information and reporting
requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with this law, file periodic reports, proxy statements
and other information with the SEC. These periodic reports, proxy statements and other information are available on the website of the
SEC referred to above. We maintain a website at https://bioviepharma.com/. Information